Highest-materiality recent filing
Zeo ScientifiX Q1 FY2026 revenue up 124.6% to $2.58M; net loss narrows to ~$1.0M
Revenue for quarter ended Apr 30, 2026: $2.58M vs $1.15M a year ago, +124.6%.
ZEO ScientifiX to host educational webinar on regenerative medicine laws in Southeast
Webinar titled 'One Year Later, Three States Stronger: The Southeast Regen Revolution' on July 22, 2026 at 6:45 p.m. ET.
ZEO donates products for pediatric burn reconstruction mission in Peru
Dr. Constantino Mendieta used ZEO-donated products to treat ~38 child burn patients in Cusco, Peru.
Fully vested options for 625,000 shares each to Greyt Ventures (consultant/stockholder), CEO Ian Bothwell, and CMO George Shapiro; exercise price $1.67, 10-year term.
ZEO ScientifiX expands Medical Advisory Board with nine new physicians in regenerative medicine
New advisors include Andrea Asseff-Llanes (dental), Elizabeth Parrish (longevity), Faryal Farooqi (metabolic), Michael Swartzon (orthopedic sports medicine), and five others.
ZeoScientifiX launches Physician-Led Patient Masterclass; trained 600+ physicians in past year
Program formalizes patient education model that emerged from a physician-hosted event in Vero Beach, Florida.
ZEO ScientifiX monthly sales top $1M in April 2026 for first time
Unaudited single-month sales surpassed $1.0 million in April 2026, a company first.
Zeo ScientifiX surpasses 500 physicians trained in regenerative medicine Masterclass series
Trained over 500 clinicians through monthly Masterclass series at Nova Southeastern University.
ZEO signs MOU to be exclusive biologics supplier for Regen Therapy's 3,000-clinic network
MOU positions ZEO as core supplier of advanced biologic therapeutics for Regen Therapy's regenerative platform.
ZEO ScientifiX selected as qualified team for XPRIZE Healthspan $101M competition semi-finals
Advancing to semi-finals of XPRIZE Healthspan; aims to develop therapeutics restoring muscle, cognitive, and immune function by 10-20 years in persons aged 65-80.
ZEO named official regenerative medicine educational partner for A4M; Masterclass Apr 9
Role as official educational partner for regenerative medicine with A4M at Longevity SpringFest 2026.
Zeo ScientifiX terminates Chief Science Officer Dr. John D. Kisiday
Zeo ScientifiX terminated Dr. John D. Kisiday as Chief Science Officer, effective March 23, 2026.
Zeo ScientifiX appoints Dr. John Kisiday as CSO with salary $175K and 50K stock grant
Dr. Kisiday, 55, has 30 years experience in tissue-engineering and regenerative medicine; started Jan 23, 2026.
Zeo ScientifiX awards 350k restricted shares to CEO/CFO and CMO
Each officer (Ian Bothwell, CEO/CFO; Dr. George Shapiro, CMO) granted 175,000 restricted shares.
Zeo partners to commercialize Cytora's oral mucosal stem cell therapy under Florida law
Zeo gets exclusive U.S. commercial rights to Cytora's allogeneic oral mucosal stem cell therapy (hOMSC200).
Ian Bothwell appointed full-time CEO of Zeo ScientifiX, retains CFO role
Board appointed Ian T. Bothwell as full-time CEO effective December 24, 2025.
Zeo ScientifiX terminates Chief Sales Officer Ron Borsheim effective Nov 30, 2025
Ron Borsheim terminated as Chief Sales Officer – Aesthetics, effective November 30, 2025.
ZEO ScientifiX positioned for Florida stem cell market growth after SB 1768 enactment
Florida SB 1768, effective July 1, 2025, allows physicians to administer non-FDA-approved stem cell therapies for orthopedic, wound care, and pain under cGMP.
Zeo ScientifiX raises $1M via private placement of 250k shares
Sold 250,000 common shares to one accredited investor for $1,000,000 at $4.00 per share.
Dr. Peter Everts resigns as Chief Scientific & Technology Officer, effective Aug 1, 2025
Dr. Peter A. M. Everts, Ph.D. resigned as Chief Scientific and Technology Officer.
ZEO ScientifiX launches expansion initiative following Florida's new stem cell law
Florida's SB-1768, effective July 1, 2025, authorizes non-FDA-approved stem cell therapies for defined conditions.
ZEO launches physician masterclass ahead of Florida's SB-1768 stem cell therapy law
Florida's SB-1768, effective July 1, 2025, permits MDs and DOs to offer non-FDA-approved stem cell therapies under strict compliance.
Zeo ScientifiX issues shares/warrants to consultant; grants options to execs and directors
Issued 100,000 shares and warrants for 500,000 shares to non-affiliated consultant under Section 4(a)(2) exemption.
Appoints Ron Borsheim as Chief Sales Officer - Aesthetics effective April 1, 2025
Base salary of $225,000 per year; option to purchase 40,000 shares at $2.50/share.
ZEO ScientifiX appoints Dr. Peter A.M. Everts as Chief Scientific and Technology Officer
Dr. Everts brings 35+ years of experience in orthobiology, spine, wound care, and regenerative medicine.
Zeo ScientifiX update: Phase I Zofin trial complete, PPX revenue up $474K, partnerships expanded
Completed Phase I safety trials for flagship Zofin; plans to amend INDs for Phase II targeting Osteoarthrosis and COPD.
Zeo ScientifiX enters joint development MOU with BioXtek, appoints Dr. Peter Everts as CSO
Binding MOU with BioXtek for joint development, manufacturing, marketing, and funding arrangement.
Zeo ScientifiX amends Series C Preferred redemption terms to allow assignment with board consent
Amendment permits assignment of Series C Preferred with prior board consent without triggering redemption.
Zeo ScientiFix files 8-K/A to correct graphical error in ZEO HAIR GROW presentation slide
Original Nov 15 8-K furnished PowerPoint on ZEO HAIR GROW product; amendment corrects graphical error in one slide.
Zeo ScientifiX launches ZEO HAIR GROW exosome-based hair growth system at MAP conference
Product introduced at Medical Aesthetics Professionals meeting in Scottsdale, AZ on Nov 15, 2024.
ZEO ScientifiX and Exotropin launch ZEO HAIR GROW hair growth system at MAP meeting
ZEO HAIR GROW Powered By Exotropin, a multipart hair growth system, to be introduced at MAP meeting Nov 14-16, 2024 in Scottsdale.
ZEO ScientifiX launches monthly regenerative medicine educational series for physicians
In-person events titled 'The Future of Biologic Medicine' focus on extracellular vesicles and autologous biologics.
Zeo ScientifiX partners with Physicians Group for Phase 2 clinical trials
Physicians Group operates 75 clinics and 750+ clinicians, treating 1,500-2,000 patients monthly.
Zeo ScientifiX completes Phase 1 trials for Zofin; seeks Phase 2 trials
Completed Phase 1 clinical trials for flagship product Zofin; actively seeking to commence Phase 2 trials for multiple indications.
Zeo ScientifiX grants 700K warrants to controlling stockholders and 550K options to insiders
Warrants for 350,000 shares each granted to Skycrest Holdings and Greyt Ventures; exercise price $2.35.
Closed private financing of $500,000 with a single accredited investor on July 8, 2024.
Zeo ScientifiX loses CEO and CSO; CFO Bothwell named interim CEO
CEO Dr. Harry Leider and CSO Dr. Howard Golub employment not renewed; both left May 31, 2024.
Zeo ScientifiX awards stock grants to directors, boosts CFO salary to $250k
Stock grants of 125,000 shares to director Jerry Glauser and 62,500 to Leathem Stearn, fully vested on grant date.
Zeo ScientifiX (f/k/a Organicell) changes name and ticker to ZEOX effective March 5, 2024
FINRA approved corporate name change from Organicell Regenerative Medicine to Zeo ScientifiX and symbol from OCEL to ZEOX, effective at market open March 5, 2024.
Zeo ScientifiX (fka Organicell) name change effective Feb 20; symbol change pending FINRA
Company changed name from Organicell Regenerative Medicine, Inc. to Zeo ScientifiX, Inc. effective February 20, 2024.
Organicell Regenerative Medicine to change name to Zeo ScientifiX, Inc.
Board and stockholders approved name change on December 8, 2023.
Reverse split at 1:200 ratio effective close of business Nov 27, 2023; trading on post-split basis begins Nov 28 under ticker OCELD for 20 days.
Organicell settles with former directors; recovers 232.8M shares
Settlement with Albert Mitrani and Dr. Maria Ines Mitrani resolves Florida state action claims.
Organicell sells Basalt, CO laboratory for $1.25M plus lease assumption
Sold Basalt, Colorado laboratory facility to non-affiliated third party for $1,250,000.
Organicell reports no safety events in Phase 1/2a studies of Zofin; plans Phase 2 in 2024
No therapy-related safety events or significant adverse events across three Phase 1/2a studies with over 20 Zofin-treated patients.
Director Maria Ines Mitrani resigns from Organicell board
Dr. Maria Ines Mitrani resigned as a director effective July 11, 2023.
Organicell appoints Howard Golub as EVP/CSO; 30+ years in clinical therapeutics
Howard L. Golub, MD, PhD appointed EVP and Chief Science Officer effective June 29, 2023.
Organicell appoints Harry Leider, MD, MBA as CEO effective June 21, 2023
Dr. Leider most recently served as CMO/EVP at Gelesis, gaining FDA approval for Plenity and leading the company through a NYSE IPO.
Complaint filed June 7, 2023 in Broward County, Florida, alleging breach of contract, fiduciary duty, tortious interference.
Organicell appoints Harry Leider as CEO and Howard Golub as CSO; Chairman Modi resigns
Dr. Bhupendra Kumar Modi stepped down as Chairman and director on June 4, 2023.
Effective April 1, 2025, Ron Borsheim was appointed the Company’s Chief Sales Officer - Aesthetics.
Effective February 7, 2025, Dr. Peter A. M. Everts, Ph.D. (“ Dr. Everts” ) was appointed the Company’s Chief Scientific and Technology Officer.
Dr. Leider no longer serves as a director of ZEO, as provided for therein.
the employment agreements expired and the employment of Drs. Leider and Golub by the Company ended on May 31, 2024.
the employment agreements expired and the employment of Drs. Leider and Golub by the Company ended on May 31, 2024.
Effective June 1, 2024, our board of directors appointed Ian T. Bothwell, the Company’s Chief Financial Officer to serve in the additional position of Interim Chief Executive Officer
On July 11, 2023, Dr. Maria Ines Mitrani resigned as a director of the Company.
On June 6, 2023, our board of directors appointed Harry Leider, M.D., M.B.A., as Chief Executive Officer and a member of the board of directors
and Howard J. Golub, M.D., as Executive Vice President and Chief Science Officer.
On June 4, 2023, Dr. Bhupendra Kumar Modi stepped down as Chairman of the Board and a director of Organicell.
On May 12, 2023, Organicell terminated Albert Mitrani as its Executive Vice President of Sales and contemporaneously terminated his employment agreement with the Company.
On April 28, 2023, Organicell terminated Dr. Maria Ines Mitrani as its Chief Scientific Officer and contemporaneously terminated her employment agreement with the Company.
Max materiality 0.75 · Median 0.50 · Most common event other_material